PTGR1

Summary

PTGR1 (prostaglandin reductase 1, HGNC:18429) is a protein-coding gene on chromosome 9q31.3, encoding Prostaglandin reductase 1 (Q14914). NAD(P)H-dependent oxidoreductase involved in metabolic inactivation of pro- and anti-inflammatory eicosanoids: prostaglandins (PG), leukotrienes (LT) and lipoxins (LX).

This gene encodes an enzyme that is involved in the inactivation of the chemotactic factor, leukotriene B4. The encoded protein specifically catalyzes the NADP+ dependent conversion of leukotriene B4 to 12-oxo-leukotriene B4. A pseudogene of this gene is found on chromosome 1. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 22949 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 77 total
• Druggable target: yes
• MANE Select transcript: NM_001146108

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18429
Approved symbol	PTGR1
Name	prostaglandin reductase 1
Location	9q31.3
Locus type	gene with protein product
Status	Approved
Aliases	ZADH3
Ensembl gene	ENSG00000106853
Ensembl biotype	protein_coding
OMIM	601274
Entrez	22949

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 24 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000309195, ENST00000374308, ENST00000374313, ENST00000374324, ENST00000407693, ENST00000422125, ENST00000466771, ENST00000485319, ENST00000538962, ENST00000878675, ENST00000878676, ENST00000878677, ENST00000878678, ENST00000878679, ENST00000878680, ENST00000878681, ENST00000878682, ENST00000878683, ENST00000878684, ENST00000878685, ENST00000878686, ENST00000878687, ENST00000916460, ENST00000916461, ENST00000916462, ENST00000916463, ENST00000947724, ENST00000947725, ENST00000947726

RefSeq mRNA: 3 — MANE Select: NM_001146108 NM_001146108, NM_001146109, NM_012212

CCDS: CCDS55331, CCDS6779

Canonical transcript exons

ENST00000407693 — 10 exons

Exon	Start	End
ENSE00001550419	111599603	111599647
ENSE00003556058	111597317	111597432
ENSE00003802362	111578796	111578951
ENSE00003804466	111585998	111586165
ENSE00003804741	111570091	111570209
ENSE00003807576	111594222	111594267
ENSE00003807961	111574734	111574842
ENSE00003810161	111583472	111583589
ENSE00003844330	111562567	111563231
ENSE00003893846	111592926	111592982

Expression profiles

Bgee: expression breadth ubiquitous, 258 present calls, max score 99.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.3599 / max 1285.2682, expressed in 1571 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102019	20.4494	1488
102018	18.7817	1522
102020	6.1601	1340
205596	0.5665	327
102021	0.4022	209

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	99.69	gold quality
kidney epithelium	UBERON:0004819	99.60	gold quality
ileal mucosa	UBERON:0000331	99.45	gold quality
esophagus squamous epithelium	UBERON:0006920	99.05	gold quality
right lobe of liver	UBERON:0001114	98.99	gold quality
pancreatic ductal cell	CL:0002079	98.90	gold quality
liver	UBERON:0002107	98.89	gold quality
islet of Langerhans	UBERON:0000006	98.64	gold quality
duodenum	UBERON:0002114	98.55	gold quality
gingival epithelium	UBERON:0001949	98.41	gold quality
gingiva	UBERON:0001828	98.39	gold quality
adult mammalian kidney	UBERON:0000082	98.11	gold quality
right adrenal gland cortex	UBERON:0035827	98.04	gold quality
right adrenal gland	UBERON:0001233	97.99	gold quality
kidney	UBERON:0002113	97.58	gold quality
renal medulla	UBERON:0000362	97.51	gold quality
left adrenal gland	UBERON:0001234	97.46	gold quality
left adrenal gland cortex	UBERON:0035825	97.23	gold quality
esophagus mucosa	UBERON:0002469	97.21	gold quality
oral cavity	UBERON:0000167	97.20	gold quality
gall bladder	UBERON:0002110	96.98	gold quality
adrenal cortex	UBERON:0001235	96.90	gold quality
stromal cell of endometrium	CL:0002255	96.70	gold quality
small intestine	UBERON:0002108	96.61	gold quality
caput epididymis	UBERON:0004358	96.48	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.43	gold quality
metanephros	UBERON:0000081	96.42	gold quality
adrenal gland	UBERON:0002369	96.37	gold quality
metanephros cortex	UBERON:0010533	96.34	gold quality
corpus epididymis	UBERON:0004359	96.24	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	804.93
E-HCAD-10	yes	34.51
E-MTAB-10553	yes	30.23
E-MTAB-3929	no	280.51
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting PTGR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-190B-3P	99.33	68.29	1382
HSA-MIR-1911-5P	98.92	67.53	325
HSA-MIR-224-3P	98.91	68.42	1815
HSA-MIR-522-3P	98.91	68.56	1817
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-4477A	98.83	69.75	2952
HSA-MIR-3129-3P	97.85	67.63	1246
HSA-MIR-5583-5P	97.85	67.61	1243
HSA-MIR-1255B-2-3P	97.80	67.04	880
HSA-MIR-562	97.66	65.63	698

Literature-anchored findings (GeneRIF, showing 8)

• restoration of expression in enzyme-negative lung cancer cell lines induces apoptosis and growth inhibition (PMID:19595472)
• Data show that two genes, LTB4DH and DPYSL3, were confirmed to be candidate genes for the predictor of a good immune response. (PMID:20804502)
• These results situate PtGR-1 as a critical modulator of both the steady state levels and signaling activities of fatty acid nitroalkenes in vivo. (PMID:23878198)
• selenium had only a minor influence on prostaglandin reductase 1 (PTGR1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and protein levels (PMID:25179160)
• The data indicate that HMGB1-miR-522-3p-PTGR1 axis may be involved in the abnormal resolution of inflammation and suggest that this mechanism might be a target for modulation of chronic inflammatory disorder. (PMID:28088550)
• LTB4DH plays a pivotal role in alpha-galactosylceramide-pulsed dendritic cell immunotherapy for non-small cell lung cancer. (PMID:30336981)
• PTGR1 is involved in cell proliferation in thoracic ossification of the ligamentum flavum. (PMID:37910537)
• The human PTGR1 gene expression is controlled by TE-derived Z-DNA forming sequence cooperating with miR-6867-5p. (PMID:38413664)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptgr1.1	ENSDARG00000024877
danio_rerio	ptgr1.2	ENSDARG00000087017
mus_musculus	Ptgr1	ENSMUSG00000028378
rattus_norvegicus	Ptgr1	ENSRNOG00000015072
caenorhabditis_elegans		WBGENE00010790
caenorhabditis_elegans		WBGENE00010791
caenorhabditis_elegans		WBGENE00017060

Paralogs (17): VAT1 (ENSG00000108828), TP53I3 (ENSG00000115129), MECR (ENSG00000116353), CRYZ (ENSG00000116791), RTN4IP1 (ENSG00000130347), PTGR2 (ENSG00000140043), SORD (ENSG00000140263), VAT1L (ENSG00000171724), ADH6 (ENSG00000172955), PTGR3 (ENSG00000180011), ADH1A (ENSG00000187758), ADH7 (ENSG00000196344), ADH1B (ENSG00000196616), ADH5 (ENSG00000197894), ADH4 (ENSG00000198099), CRYZL1 (ENSG00000205758), ADH1C (ENSG00000248144)

Protein

Protein identifiers

Prostaglandin reductase 1 — Q14914 (reviewed: Q14914)

Alternative names: 15-oxoprostaglandin 13-reductase, Dithiolethione-inducible gene 1 protein, Leukotriene B4 12-hydroxydehydrogenase, NAD(P)H-dependent alkenal/one oxidoreductase

All UniProt accessions (4): Q14914, F2Z3J9, F6XGT7, Q5JVP2

UniProt curated annotations — full annotation on UniProt →

Function. NAD(P)H-dependent oxidoreductase involved in metabolic inactivation of pro- and anti-inflammatory eicosanoids: prostaglandins (PG), leukotrienes (LT) and lipoxins (LX). Catalyzes with high efficiency the reduction of the 13,14 double bond of 15-oxoPGs, including 15-oxo-PGE1, 15-oxo-PGE2, 15-oxo-PGF1-alpha and 15-oxo-PGF2-alpha. Catalyzes with lower efficiency the oxidation of the hydroxyl group at C12 of LTB4 and its derivatives, converting them into biologically less active 12-oxo-LTB4 metabolites. Reduces 15-oxo-LXA4 to 13,14 dihydro-15-oxo-LXA4, enhancing neutrophil recruitment at the inflammatory site. May play a role in metabolic detoxification of alkenals and ketones. Reduces alpha,beta-unsaturated alkenals and ketones, particularly those with medium-chain length, showing highest affinity toward (2E)-decenal and (3E)-3-nonen-2-one. May inactivate 4-hydroxy-2-nonenal, a cytotoxic lipid constituent of oxidized low-density lipoprotein particles.

Subunit / interactions. Monomer or homodimer.

Subcellular location. Cytoplasm.

Tissue specificity. High expression in the kidney, liver, and intestine but not in leukocytes.

Similarity. Belongs to the NADP-dependent oxidoreductase L4BD family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14914-1	1	yes
Q14914-2	2

RefSeq proteins (3): NP_001139580, NP_001139581, NP_036344 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011032	GroES-like_sf	Homologous_superfamily
IPR013149	ADH-like_C	Domain
IPR014190	PTGR1	Family
IPR020843	ER	Domain
IPR036291	NAD(P)-bd_dom_sf	Homologous_superfamily
IPR041694	ADH_N_2	Domain
IPR045010	MDR_fam	Family

Pfam: PF00107, PF16884

Catalyzed reactions (Rhea), 12 shown:

• 13,14-dihydro-15-oxo-prostaglandin E2 + NADP(+) = 15-oxoprostaglandin E2 + NADPH + H(+) (RHEA:11912)
• an n-alkanal + NADP(+) = an alk-2-enal + NADPH + H(+) (RHEA:13737)
• 13,14-dihydro-15-oxo-prostaglandin E1 + NADP(+) = 15-oxoprostaglandin E1 + NADPH + H(+) (RHEA:50584)
• 13,14-dihydro-15-oxo-PGF2alpha + NADP(+) = 15-oxoprostaglandin F2alpha + NADPH + H(+) (RHEA:50588)
• 13,14-dihydro-15-oxo-prostaglandin F1alpha + NADP(+) = 15-oxoprostaglandin F1alpha + NADPH + H(+) (RHEA:50592)
• leukotriene B4 + NADP(+) = 12-oxo-leukotriene B4 + NADPH + H(+) (RHEA:50608)
• decanal + NADP(+) = (2E)-decenal + NADPH + H(+) (RHEA:50612)
• nonan-2-one + NADP(+) = (3E)-nonen-2-one + NADPH + H(+) (RHEA:50616)
• hexanal + NADP(+) = (E)-hex-2-enal + NADPH + H(+) (RHEA:50776)
• octanal + NADP(+) = (2E)-octenal + NADPH + H(+) (RHEA:50780)
• dodecanal + NADP(+) = (2E)-dodecenal + NADPH + H(+) (RHEA:50784)
• pentan-2-one + NADP(+) = (E)-pent-3-en-2-one + NADPH + H(+) (RHEA:50788)

UniProt features (49 total): strand 15, helix 15, binding site 7, modified residue 4, mutagenesis site 2, turn 2, chain 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
9D6Z	X-RAY DIFFRACTION	1.75
9D6X	X-RAY DIFFRACTION	1.95
9D71	X-RAY DIFFRACTION	2
9MDE	X-RAY DIFFRACTION	2
9D6W	X-RAY DIFFRACTION	2.1
9MDF	X-RAY DIFFRACTION	2.1
2Y05	X-RAY DIFFRACTION	2.2
1ZSV	X-RAY DIFFRACTION	2.3
9MDH	X-RAY DIFFRACTION	2.3
9D6Y	X-RAY DIFFRACTION	2.35

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14914-F1	97.43	0.99

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 152–155; 178; 193; 217; 239–245; 270–272; 321

Post-translational modifications (4): 178, 178, 18, 20

Mutagenesis-validated functional residues (2):

Position	Phenotype
56	markedly decreases the catalytic efficiency toward 15-oxoprostaglandin e2.
245	markedly decreases the catalytic efficiency toward 15-oxoprostaglandin e2 and (3e)-3-nonen-2-one.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2142691	Synthesis of Leukotrienes (LT) and Eoxins (EX)
R-HSA-2142700	Biosynthesis of Lipoxins (LX)

MSigDB gene sets: 222 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, HOFFMANN_SMALL_PRE_BII_TO_IMMATURE_B_LYMPHOCYTE_DN, XU_GH1_AUTOCRINE_TARGETS_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_CH_GROUP_OF_DONORS, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, ROZANOV_MMP14_TARGETS_UP, HSIAO_LIVER_SPECIFIC_GENES

GO Biological Process (6): leukotriene metabolic process (GO:0006691), prostaglandin metabolic process (GO:0006693), leukotriene B4 metabolic process (GO:0036102), lipoxin A4 metabolic process (GO:2001302), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631)

GO Molecular Function (8): 2-alkenal reductase (NADPH) activity (GO:0035798), 13-lipoxin reductase activity (GO:0036185), 15-oxoprostaglandin 13-reductase [NAD(P)+] activity (GO:0047522), leukotriene B4 12-hydroxy dehydrogenase activity (GO:0097257), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor (GO:0016628), 2-alkenal reductase [NAD(P)H] activity (GO:0032440)

GO Cellular Component (2): cytoplasm (GO:0005737), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Arachidonate metabolism	1
Biosynthesis of specialized proresolving mediators (SPMs)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
long-chain fatty acid metabolic process	2
fatty acid derivative metabolic process	2
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor	2
icosanoid metabolic process	1
prostanoid metabolic process	1
leukotriene metabolic process	1
unsaturated fatty acid metabolic process	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
2-alkenal reductase [NAD(P)H] activity	1
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	1
oxidoreductase activity, acting on CH-OH group of donors	1
binding	1
catalytic activity	1
oxidoreductase activity, acting on the CH-CH group of donors	1
intracellular anatomical structure	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

1226 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTGR1	HPGD	P15428	565
PTGR1	DHCR24	Q15392	514
PTGR1	LTA4H	P09960	488
PTGR1	ARG2	P78540	452
PTGR1	NQO1	P15559	433
PTGR1	ARG1	P05089	432
PTGR1	PTGER4	P35408	422
PTGR1	BPIFB2	Q8N4F0	414
PTGR1	AKR1C1	P52896	410
PTGR1	MGAT4B	Q9UQ53	391
PTGR1	TXNRD1	Q16881	384
PTGR1	ARCN1	P48444	375
PTGR1	DSC3	Q14574	374
PTGR1	PTGES	O14684	363
PTGR1	METAP1D	Q6UB28	347

IntAct

12 interactions, top by confidence:

A	B	Type	Score
PTGR1	JPH3	psi-mi:“MI:0915”(physical association)	0.560
ENG	IGKV2-28	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
	TNFRSF10A	psi-mi:“MI:0914”(association)	0.350
SRRT	A2ML1	psi-mi:“MI:0914”(association)	0.350
MRPL49	UBA6	psi-mi:“MI:0914”(association)	0.350
SMPD2	A2ML1	psi-mi:“MI:0914”(association)	0.350
OBI1	PTGR1	psi-mi:“MI:0915”(physical association)	0.000
PTGR1	ychF	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (65): ADH5 (Co-fractionation), ADK (Co-fractionation), AKR1A1 (Co-fractionation), ASS1 (Co-fractionation), CFL1 (Co-fractionation), GOT1 (Co-fractionation), GOT2 (Co-fractionation), HINT1 (Co-fractionation), PRDX6 (Co-fractionation), PTGR1 (Co-fractionation), PTGR1 (Affinity Capture-MS), PTGR1 (Affinity Capture-MS), PTGR1 (Affinity Capture-MS), PTGR1 (Affinity Capture-MS), PTGR1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D2YG03, A0A161CAI1, A0A3Q9U4Z5, A0A8F4S717, A0A8K1AWG4, A0A9E7LUR3, B2NI93, B8NTZ8, E5AE42, G4MVZ3, N4WR35, O34812, O42909, O94564, P0DXJ1, P25377, P25608, P53912, P54007, P76113, P93243, P97584, Q03102, Q0V6Q3, Q14914, Q28719, Q29073, Q32L99, Q39172, Q39173, Q3SZJ4, Q5BK81, Q5R806, Q6WAU0, Q8H0M1, Q8J0F9, Q8N8N7, Q8VDQ1, Q91YR9, Q9C0Y6

Diamond homologs: A0A0D2YG03, A0A4P8DJV2, A5ABG0, B8NTZ8, D7UPN2, N4WR35, O34812, P97584, Q14914, Q28719, Q29073, Q39172, Q39173, Q3SZJ4, Q5BA83, Q6WAU0, Q86ZD9, Q91YR9, Q9C0Y6, Q9EQZ5, Q9SLN8, S0DRW9, W7NCN7, A0A345BJP0, A0A3G1DJH7, P76113, Q24K16, Q32L99, Q5BK81, Q5R806, Q8N8N7, Q8VDQ1, G0LET7, O00097, O23939, P08843, P42865, Q03102, Q5AY39, Q84V25

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1567 predictions. Top by Δscore:

Variant	Effect	Δscore
9:111570086:CTTA:C	donor_loss	1.0000
9:111570087:TTAC:T	donor_loss	1.0000
9:111570088:TA:T	donor_loss	1.0000
9:111570089:A:AC	donor_gain	1.0000
9:111570090:C:CC	donor_gain	1.0000
9:111570090:CCT:C	donor_gain	1.0000
9:111570210:C:CC	acceptor_gain	1.0000
9:111574839:CTAC:C	acceptor_gain	1.0000
9:111578792:TTA:T	donor_loss	1.0000
9:111578794:A:AC	donor_gain	1.0000
9:111578794:ACATT:A	donor_loss	1.0000
9:111578795:C:CA	donor_gain	1.0000
9:111578795:CA:C	donor_gain	1.0000
9:111578795:CAT:C	donor_gain	1.0000
9:111578795:CATT:C	donor_gain	1.0000
9:111578795:CATTA:C	donor_gain	1.0000
9:111578947:CAGCC:C	acceptor_gain	1.0000
9:111578948:AGCC:A	acceptor_gain	1.0000
9:111578949:GCC:G	acceptor_gain	1.0000
9:111578950:CC:C	acceptor_gain	1.0000
9:111578950:CCC:C	acceptor_gain	1.0000
9:111578951:CC:C	acceptor_gain	1.0000
9:111578952:C:CC	acceptor_gain	1.0000
9:111578952:C:CG	acceptor_loss	1.0000
9:111578952:C:T	acceptor_gain	1.0000
9:111578956:G:C	acceptor_gain	1.0000
9:111583467:CTTA:C	donor_loss	1.0000
9:111583468:TTACC:T	donor_loss	1.0000
9:111583469:TAC:T	donor_loss	1.0000
9:111583470:A:AG	donor_loss	1.0000

AlphaMissense

2132 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:111586104:A:G	W91R	0.992
9:111586104:A:T	W91R	0.992
9:111578802:A:C	F215L	0.989
9:111578802:A:T	F215L	0.989
9:111578804:A:G	F215L	0.989
9:111583581:G:T	A129D	0.986
9:111574775:C:T	G240E	0.985
9:111583523:A:C	N148K	0.984
9:111583523:A:T	N148K	0.984
9:111583482:G:T	A162E	0.983
9:111594234:T:C	D47G	0.983
9:111594234:T:A	D47V	0.982
9:111594240:G:A	T45I	0.982
9:111574777:A:C	C239W	0.981
9:111592930:C:G	A69P	0.980
9:111574793:C:T	G234E	0.979
9:111583527:A:T	V147D	0.978
9:111574778:C:T	C239Y	0.977
9:111578796:A:C	N217K	0.976
9:111578796:A:T	N217K	0.976
9:111578800:T:A	D216V	0.976
9:111578801:C:G	D216H	0.976
9:111583518:G:T	A150E	0.976
9:111563139:C:A	K324N	0.975
9:111563139:C:G	K324N	0.975
9:111574784:G:T	A237D	0.975
9:111574817:A:T	V226D	0.975
9:111578935:C:T	G171E	0.975
9:111583503:C:T	G155D	0.975
9:111574793:C:A	G234V	0.974

dbSNP variants (sampled 300 via entrez): RS1000032156 (9:111567663 T>C), RS1000083892 (9:111567971 G>T), RS1000088513 (9:111554439 C>G,T), RS1000184966 (9:111593133 G>C), RS1000295377 (9:111586637 T>A,G), RS1000300035 (9:111555015 G>A), RS1000331823 (9:111562164 C>T), RS1000367228 (9:111599739 G>A,C), RS1000448330 (9:111579664 C>T), RS1000468560 (9:111592826 A>C), RS1000538057 (9:111598376 T>C), RS1000692079 (9:111587107 G>A), RS1000728768 (9:111579192 G>A), RS1000756515 (9:111585456 G>A), RS1000821206 (9:111599956 G>C)

Disease associations

OMIM: gene MIM:601274 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001887_3	Monocyte count	5.000000e-07
GCST003993_7	Menarche (age at onset)	2.000000e-08
GCST006585_2714	Blood protein levels	2.000000e-38
GCST008762_8	Intake of sweets	3.000000e-07
GCST008839_537	Height	4.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005091	monocyte count
EFO:0004703	age at menarche
EFO:0010158	sugar consumption measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295822 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

112 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects expression, decreases expression, increases expression, increases methylation	10
Valproic Acid	affects cotreatment, increases expression	5
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	3
Particulate Matter	affects expression, increases reaction, increases expression, decreases expression, increases abundance	3
bisphenol A	decreases expression, affects expression	2
lead acetate	increases expression	2
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
cobaltous chloride	affects cotreatment, increases expression	2
acylfulvene	affects reaction, increases response to substance, increases activity	2
Arsenic Trioxide	increases expression	2
Acetaminophen	decreases expression	2
Vehicle Emissions	affects expression, increases reaction, decreases expression, increases abundance	2
Cisplatin	affects cotreatment, increases expression, affects expression	2
Fluorouracil	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tretinoin	decreases expression, increases expression	2
Cyclosporine	decreases expression, increases expression	2
Lactic Acid	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
15-keto-13,14-dihydroprostaglandin F2alpha	increases abundance, increases metabolic processing	1
15-ketoprostaglandin E	increases metabolic processing, increases abundance	1
trichostatin A	increases expression	1
nimesulide	affects activity	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction	1
sulforaphane	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118750	Binding	Binding affinity to PTGR1 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2CP	Abcam HeLa PTGR1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.